English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Editorial Interests in global organ diseases have accelerated with links between nonalcoholic fatty liver disease (NAFLD) and various chronic diseases with relevance to the metabolic syndrome and neurodegenerative diseases. Early diagnosis of global organ disease involve genomic, lipidomic and proteomic biomarker tests that may diagnose early neuron dysfunction with the prevention of various organ diseases [1]. Diet and nutrition are closely linked to accelerated aging and may allow biomarker tests to provide adequate information with relevance to the immune system dysfunction and the severity of chronic diseases. In spite of various biomarker tests and analyte measurements for chronic diseases such as obesity and diabetes abnormal nuclear-mitochondria interactions [2] persist with inflammation involved in the induction of programmed cell death.

The Future of Biomarkers Tests and Genomic Medicine in Global Organ Disease